Mobilization characteristics and strategies to improve hematopoietic progenitor cell mobilization and collection in patients with chronic granulomatous disease and severe combined immunodeficiency

Transfusion

Volumn 55, Issue 2, 2015, Pages 265-274

  Panch, Sandhya R ^a   Yau, Yu Ying ^b   Kang, Elizabeth M ^c   De Ravin, Suk See ^c   Malech, Harry L ^c   Leitman, Susan F ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; COTRIMOXAZOLE; FILGRASTIM; GAMMA INTERFERON; HEMOGLOBIN; ITRACONAZOLE; PLERIXAFOR; PREDNISONE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; APHERESIS; ARTICLE; CASE CONTROL STUDY; CELL COUNT; CHRONIC GRANULOMATOUS DISEASE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; RETROSPECTIVE STUDY; SEVERE COMBINED IMMUNODEFICIENCY; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; UNSPECIFIED SIDE EFFECT; YOUNG ADULT; AUTOGRAFT; CHILD; CLINICAL TRIAL; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORTALITY; PROCEDURES;

ADOLESCENT; ADULT; AUTOGRAFTS; BLOOD COMPONENT REMOVAL; CHILD; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; RETROSPECTIVE STUDIES; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 84922980714     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12830     Document Type: Article

References (33)

1. Buckley RH,. The multiple causes of human SCID. J Clin Invest 2004; 114: 1409-1411.
2. Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 2010; 45: 246-265.
3. Segal BH, Veys P, Malech H, et al. Chronic granulomatous disease: lessons from a rare disorder. Biol Blood Marrow Transplant 2011; 17: S123-131.
4. Rivat C, Santilli G, Gaspar HB, et al. Gene therapy for primary immunodeficiencies. Hum Gene Ther 2012; 23: 668-675.
5. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, et al. Gene therapy for primary immunodeficiencies: part 1. Curr Opin Immunol 2012; 24: 580-584.
6. Neben S, Marcus K, Mauch P,. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 1993; 81: 1960-1967.
7. Motabi IH, DiPersio JF,. Advances in stem cell mobilization. Blood Rev 2012; 26: 267-278.
8. Sekhsaria S, Fleisher TA, Vowells S, et al. Granulocyte colony-stimulating factor recruitment of CD34+ progenitors to peripheral blood: impaired mobilization in chronic granulomatous disease and adenosine deaminase-deficient severe combined immunodeficiency disease patients. Blood 1996; 88: 1104-1112.
9. Cassel A, Cottler-Fox M, Doren S, et al. Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells. Exp Hematol 1993; 21: 585-591.
10. Li F, Linton GF, Sekhsaria S, et al. CD34+ peripheral blood progenitors as a target for genetic correction of the two flavocytochrome b558 defective forms of chronic granulomatous disease. Blood 1994; 84: 53-58.
11. Aiuti A, Roncarolo MG,. Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program 2009; 682-689.
12. Vasu S, Leitman SF, Tisdale JF, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood 2008; 112: 2092-2100.
13. Wang TF, Chen SH, Yang SH, et al. Poor harvest of peripheral blood stem cell in donors with microcytic red blood cells. Transfusion 2013; 53: 91-95.
14. Chow S, Lazo-Langner A, Ormond G, et al. Predictors of unsuccessful mobilization with granulocyte colony-stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation. J Clin Apher 2013; 28: 285-292.
15. Kuittinen T, Nousiainen T, Halonen P, et al. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907-912.
16. Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718-723.
17. Tournilhac O, Cazin B, Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363-365.
18. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874.
19. Jantunen E, Lemoli RM,. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion 2012; 52: 906-914.
20. Quinton LJ, Nelson S, Boe DM, et al. The granulocyte colony-stimulating factor response after intrapulmonary and systemic bacterial challenges. J Infect Dis 2002; 185: 1476-1482.
21. Kang EM, Malech HL,. Gene therapy for chronic granulomatous disease. Methods Enzymol 2012; 507: 125-154.
22. Fowler CJ, Yau YY, Bolan CD, et al. Analysis of donor demographic and laboratory parameters affecting CD34+ cell mobilization in healthy allogeneic pediatric peripheral blood stem cell (PBSC) donors. Blood 2010; 116: 2259A.
23. Bolan CD, Carter CS, Wesley RA, et al. Prospective evaluation of cell kinetics, yields and donor experiences during a single large-volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells. Br J Haematol 2003; 120: 801-807.
24. Bolan CD, Cecco SA, Wesley RA, et al. Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion 2002; 42: 935-946.
25. Boulton F,. Evidence-based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation-induced iron depletion. Transfus Med 2008; 18: 13-27.
26. US Department of Health and Human Services/National Institutes of Health/National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. USDHHS/NIH/NCI. June 14, 2010. [cited 2014 Apr 17]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html
27. Ott MG, Merget-Millitzer H, Ottmann OG, et al. Mobilization and transduction of CD34(+) peripheral blood stem cells in patients with X-linked chronic granulomatous disease. J Hematother Stem Cell Res 2002; 11: 683-694.
28. King KY, Goodell MA,. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat Rev Immunol 2011; 11: 685-692.
29. Maciejewski J, Selleri C, Anderson S, et al. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995; 85: 3183-3190.
30. Sato T, Selleri C, Anderson S, et al. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br J Haematol 1997; 97: 356-365.
31. Jantunen E, Kvalheim G,. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. Eur J Haematol 2010; 85: 463-471.
32. Donahue RE, Jin P, Bonifacino AC, et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood 2009; 114: 2530-2541.
33. Uchida N, Bonifacino A, Krouse AE, et al. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor. Exp Hematol 2011; 39: 795-805.